about
PSMA-specific CAR-engineered T cells eradicate disseminated prostate cancer in preclinical modelsBroad-spectrum inhibition of HIV-1 by a monoclonal antibody directed against a gp120-induced epitope of CD4.In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB)Computational design of novel peptidomimetic inhibitors of cadherin homophilic interactions.Rigorous optimization and validation of potent RNA CAR T cell therapy for the treatment of common epithelial cancers expressing folate receptorProtective versus pathogenic anti-CD4 immunity: insights from the study of natural resistance to HIV infection.Redirection of T-cell effector functions for cancer therapy: bispecific antibodies and chimeric antigen receptors.In vivo imaging of prostate cancer using an anti-PSMA scFv fragment as a probe.Effect of radiochemical modification on biodistribution of scFvD2B antibody fragment recognising prostate specific membrane antigen.Targeting FR-expressing cells in ovarian cancer with Fab-functionalized nanoparticles: a full study to provide the proof of principle from in vitro to in vivo.Harnessing engineered antibodies of the IgE class to combat malignancy: initial assessment of FcɛRI-mediated basophil activation by a tumour-specific IgE antibody to evaluate the risk of type I hypersensitivity.Shed HER2 extracellular domain in HER2-mediated tumor growth and in trastuzumab susceptibility.(177)Lu- labeled MOv18 as compared to (131)I- or (90)Y-labeled MOv18 has the better therapeutic effect in eradication of alpha folate receptor-expressing tumor xenografts.Conversion of murine antibodies to human antibodies and their optimization for ovarian cancer therapy targeted to the folate receptor.Redirected activity of human antitumor chimeric immune receptors is governed by antigen and receptor expression levels and affinity of interaction.Complement activated by chimeric anti-folate receptor antibodies is an efficient effector system to control ovarian carcinoma.Highly efficient redirected anti-tumor activity of human lymphocytes transduced with a completely human chimeric immune receptor.A novel isoform of pro-interleukin-18 expressed in ovarian tumors is resistant to caspase-1 and -4 processing.CD95-mediated apoptosis is impaired at receptor level by cellular FLICE-inhibitory protein (long form) in wild-type p53 human ovarian carcinoma.Characterization of a mouse-human chimeric antibody to a cancer-associated antigen.A single-chain fragment against prostate specific membrane antigen as a tool to build theranostic reagents for prostate cancer.Reversion of transformed phenotype in ovarian cancer cells by intracellular expression of anti folate receptor antibodies.The use of a tropism-modified measles virus in folate receptor-targeted virotherapy of ovarian cancer.90Y Labeling of monoclonal antibody MOv18 and preclinical validation for radioimmunotherapy of human ovarian carcinomas.CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo.Activation of the osteopontin/matrix metalloproteinase-9 pathway correlates with prostate cancer progression.Design, selection and optimization of an anti-TRAIL-R2/anti-CD3 bispecific antibody able to educate T cells to recognize and destroy cancer cellsApproaches to implement bispecific antibody treatment of ovarian carcinomaSingle-step purification of immunotoxins containing a high ionic charge ribosome inactivating protein clavin by carboxymethyl high-performance membrane chromatographyAnti-PSMA 124I-scFvD2B as a new immuno-PET tool for prostate cancer: preclinical proof of principleDevelopment of 177Lu-scFvD2B as a Potential Immunotheranostic Agent for Tumors Overexpressing the Prostate Specific Membrane Antigen
P50
Q27339832-BD47E5F4-C54F-4A7F-97B7-271D7039A1CAQ33983104-9D03A2A4-C9AA-4A98-A7F5-24B450B36011Q34073529-12B3FD6D-608E-40CE-801F-ED692A920C17Q35547645-F25D6F1E-7295-42AA-AD37-A4EB6C7ABA94Q36557169-0C92C7A5-5EBD-429D-BCAC-E43349B8CBD3Q37460580-F84B0D89-1AFD-40F5-95F7-E1CBB00D3DB0Q38096411-FF231189-C876-4851-87C9-E29056C55182Q38784721-329E89CF-9997-446A-AC7E-4B0224E20213Q38832657-0423E0EB-F79D-4C7D-9518-693AD84799C8Q38928745-D33CF0FD-C970-41E8-8F90-E496BFABA7F1Q39543380-0DA1DC0E-B1D4-4A0E-B8CB-3A99AB785C18Q39699623-17AB234C-16C7-4F6E-8369-BCDC13D4CA80Q39805846-5D6C0487-63C9-4721-8EFF-4379DAC65ECEQ40059215-09499756-811A-46F8-A29D-A188D889A644Q40076587-1AA8C2C8-037A-4674-9944-078C72CE146DQ40296292-7D5D7897-3A03-4341-A5E8-22BC4C2272B4Q40493306-215BD647-2A63-46D6-8033-1CD814D183B4Q40522869-4D7935BF-24F9-4C2B-A69D-18B396D12CC1Q40527978-87B8B518-A40E-4CED-8E50-512D0E3509CEQ41598230-D2883A74-EAA0-4AE1-9A9C-8F1C6768AE81Q44430715-DB737A2F-298C-436D-B64E-F5EF33FA7934Q44459409-431AB5AB-E844-4F68-835A-BB81AFF0DA9FQ45410754-2612D881-C2CF-4AE7-BE69-021C98794422Q46519117-35FA2EE4-32A1-4F3F-8228-AC376CA16B6CQ50062607-D72E68FA-0582-4317-BAFA-8BB2EA601705Q54788220-F5DEC4BC-D22A-43FC-80C5-2E6CD1C873F2Q59134014-898855FD-EBF6-4473-A48E-CADF431AD5EFQ59134328-374349A5-EE56-46B6-93E3-CF4D8D11CA5FQ63204527-B3679ED5-26ED-4C33-B85C-F348CC46D89DQ92132033-7EF2F019-712D-4DC1-AAC2-FE83778BB5A2Q96230053-0B5501E9-DEA3-4455-BCFF-4085ABFEEB40
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Mariangela Figini
@ast
Mariangela Figini
@en
Mariangela Figini
@es
Mariangela Figini
@nl
Mariangela Figini
@sl
type
label
Mariangela Figini
@ast
Mariangela Figini
@en
Mariangela Figini
@es
Mariangela Figini
@nl
Mariangela Figini
@sl
prefLabel
Mariangela Figini
@ast
Mariangela Figini
@en
Mariangela Figini
@es
Mariangela Figini
@nl
Mariangela Figini
@sl
P1053
K-8753-2016
P106
P1153
7003854085
P21
P31
P3829
P496
0000-0001-9001-8754